AP NEWS

Fragile X Syndrome Pipeline Review, H2 2018 - Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

October 9, 2018

DUBLIN--(BUSINESS WIRE)--Oct 9, 2018--The “Fragile X Syndrome - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Fragile X Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2, 14, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Fragile X Syndrome - Overview Fragile X Syndrome - Therapeutics Development Fragile X Syndrome - Therapeutics Assessment Fragile X Syndrome - Companies Involved in Therapeutics Development Fragile X Syndrome - Drug Profiles Fragile X Syndrome - Dormant Projects Fragile X Syndrome - Discontinued Products Fragile X Syndrome - Product Development Milestones Appendix

Companies Mentioned

Aelis Farma SAS Anavex Life Sciences Corp Confluence Pharmaceuticals LLC DRI Biosciences Corp Eli Lilly and Co Epigen Biosciences Inc Fulcrum Therapeutics Inc GlaxoSmithKline Plc GW Pharmaceuticals Plc Healx Ltd Marinus Pharmaceuticals Inc NeuCyte Inc Neuren Pharmaceuticals Ltd Neuron Biopharma SA Novartis AG Ovid Therapeutics Inc Sage Therapeutics Inc Sentinel Oncology Ltd Tetra Discovery Partners LLC Zynerba Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bgxhk7/fragile_x?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005953/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/09/2018 12:42 PM/DISC: 10/09/2018 12:42 PM

http://www.businesswire.com/news/home/20181009005953/en

AP RADIO
Update hourly